Please refer the attachment

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults RestatedExceptional ItemResults View source PDF Explain this filing

VIJAYA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.5%Reaction day

₹1208.00

prior close

₹1269.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.2%+5.4% vs market

Healthcare Service Provider peers, median of 27sector+1.5%+4.1% vs sector

On the reaction day the stock moved 5.4 pts more than Nifty Smallcap 250 and 4.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.4

10m

-2.7

15m

-2.5

30m

-2.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.5+0.2+5.4+1.5+4.1

Next day

+10.1-0.9+11.0+1.6+8.5

+6.0-3.9+9.9-0.2+6.2

+7.0-3.6+10.6+0.0+7.0

+6.0-3.6+9.5+1.2+4.8

+11.3-3.9+15.2-0.5+11.8

+8.0-4.3+12.3-0.2+8.2

15d

+3.4-3.2+6.6+0.7+2.7

+8.1-3.8+11.9-1.0+9.1

+10.1+1.1+9.0-3.1+13.2

+15.5+5.4+10.2-3.6+19.2

UpDownMarket · Nifty Smallcap 250Sector · Healthcare Service Provider peers, median of 27Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vijaya Diagnostic Centre reported strong FY26 results with standalone revenue from operations of Rs. 76,542.88 lakhs, up 20.7% from Rs. 63,400.30 lakhs in FY25. Profit after tax grew 31.2% to Rs. 17,831.03 lakhs from Rs. 13,592.97 lakhs. EBITDA margin expanded to approximately 51% from 49% in the prior year, indicating improved operational efficiency. The board recommended a dividend of Rs. 2 per share (200%) for FY26. The company completed the amalgamation of subsidiary Medinova Diagnostic Services Limited during the year, with prior period figures restated. Statutory auditors issued an unmodified (clean) opinion on the financial results.

Likely market impact

The company delivered robust double-digit revenue and PAT growth with margin expansion, signaling operational strength. The clean audit opinion and maiden dividend recommendation are positive signals for shareholders.